Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 22, 2015

View Archived Issues

TGR-1202 enters phase I trial in solid tumors

Pembrolizumab active in patients with advanced biliary tract cancer

Neurocrine Biosciences begins phase II study of NBI-98854 in Tourette syndrome

Viking Therapeutics performs safety, tolerability and pharmacokinetic study for VK-5211

CXCR4-targeted radiotherapy with [177Lu]/[90Y]pentixather could be useful in multiple myeloma

Foamix initiates phase II trial of FMX-103 in papulopustular rosacea

Yabao Pharmaceutical licenses second diabetes candidate from Lilly

Anti-TNF antibody DLX-105 improves symptoms of Behcet's disease

OPA-15406 shows promise in phase II atopic dermatitis trial

Vitamin B12-PYY3-36 peptide conjugate reduces food intake in vivo

S-76892: a promising agent with procognitive and disease modifier properties

F-17475 is safer and more potent than ketamine in postoperative pain

Bayer Schering Pharma discloses MMP-12 inhibitors

X-Rx patents autotaxin inhibitors

Taisho Pharmaceutical presents orexin receptor antagonists

Syros Pharmaceuticals divulges CDK7 inhibitors

Acquisition and licensing agreements expand Novartis' immune-oncology pipeline

Brighton Biotech acquires license for MERS and SARS vaccines

Pfizer reports IRAK-4 inhibitors

Scancell updates pipeline progress

Biogen reports data from phase III trial of natalizumab in secondary progressive MS

Femtogenix launched to discover anticancer payloads

FDA approves Veltassa for hyperkalemia

AstraZeneca and Lilly expand immuno-oncology combination therapy collaboration

Autoimmune disease candidate ARGX-113 enters phase I trial in healthy volunteers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...